Literature DB >> 8163690

Assessment of proliferative activity in leukaemic bone marrow using the monoclonal antibody Ki-67.

D M White1, A G Smith, J L Smith.   

Abstract

AIMS: To investigate proliferative activity in leukaemic and lymphomatous bone marrow infiltrates and to assess the feasibility of transport of specimens among institutions.
METHODS: Proliferative activity in bone marrow trephine cryosections from 99 patients with non-Hodgkin's lymphoma (NHL), 23 patients with acute myeloid leukaemia (AML), 11 with acute lymphoblastic leukaemia (ALL), and two with acute undifferentiated leukaemia (AUL) was investigated. Infiltration was seen in 52 out of 99 cases of NHL on bone marrow cryosections. A score was devised to assess pathological infiltrates in bone marrow trephine cryosections using the monoclonal antibody Ki-67. This method of scoring gave a measure of non-erythroid proliferative activity.
RESULTS: Mean Ki-67 positivity in bone marrow infiltrates in 31 low grade B cell lymphomas (Kiel classification) was 0.3% before and 4.7% after treatment, 16.4% in seven high grade B cell lymphomas, and 17.8% in 12 peripheral T cell lymphomas. In 48 cases of NHL, bone marrow cryosections had not been infiltrated, and in all but one case the percentage of Ki-67 positive cells in normal marrow was less than 3%; the remaining case showed coexistent myelodysplasia and 8% bone marrow Ki-67 positivity. In eight cases of common ALL at diagnosis, the mean Ki-67 positivity in marrow cryosections was 24.9%, significantly higher than the 2.4% Ki-67 positivity seen in AML (p < 0.05). One of the two cases of common ALL with less than 1% Ki-67 positivity was refractory to treatment.
CONCLUSIONS: Proliferative activity of erythroid elements in the bone marrow varies greatly. Immunostaining of bone marrow cryosections using Ki-67 permits accurate assessment of non-erythroid proliferative activity in lymphomas and leukaemia. High grade B cell lymphomas and peripheral T cell lymphomas invading the marrow have very similar mean proliferative activities. Such levels of proliferation are of the same order as those seen in common ALL, but much higher than those seen in AML.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8163690      PMCID: PMC501896          DOI: 10.1136/jcp.47.3.209

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  16 in total

1.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.

Authors:  J Gerdes; H Lemke; H Baisch; H H Wacker; U Schwab; H Stein
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

2.  Determination of the significance of in vitro blast cell [3H]thymidine labelling indices obtained initially and serially during induction therapy of acute non-lymphocytic leukemia.

Authors:  S B Murphy; G V Dahl; S L George; J Karas; A T Look; J V Simone; A M Mauer
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

3.  Relationship between the per cent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia.

Authors:  H D Preisler; N Azarnia; A Raza; H Grunwald; R Vogler; G Browman; J Goldberg; P Chervenick; K Miller; J Brennan
Journal:  Br J Haematol       Date:  1984-03       Impact factor: 6.998

4.  Relationship of pretreatment lymphoblast proliferative activity and prognosis in 97 children with acute lymphoblastic leukemia.

Authors:  L W Dow; L J Chang; A A Tsiatis; S L Melvin; W P Bowman
Journal:  Blood       Date:  1982-06       Impact factor: 22.113

5.  Cell kinetics in acute leukemia: a critical reevaluation based on new data.

Authors:  W Hiddemann; T Büchner; M Andreeff; B Wörmann; M R Melamed; B D Clarkson
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

6.  Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients.

Authors:  H D Preisler; A Raza; R A Larson
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

7.  Lithium enhancement of megakaryocytopoiesis in culture: mediation via accessory marrow cells.

Authors:  C Chatelain; S A Burstein; L A Harker
Journal:  Blood       Date:  1983-07       Impact factor: 22.113

8.  Adult acute non-lymphoblastic leukaemia: reliability and prognostic significance of pretreatment bone marrow S-phase size determined by flow cytofluorometry.

Authors:  A Riccardi; M Danova; C Montecucco; G Ucci; E Cassano; M Giordano; G Mazzini; P Giordano
Journal:  Scand J Haematol       Date:  1986-01

9.  Prognotic significance of pretreatment proliferative activity in adult acute leukemia.

Authors:  J S Hart; S L George; E Frei; G P Bodey; R C Nickerson; E J Freireich
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

10.  Significant non-S-phase DNA synthesis visualized by flow cytometry in activated and in malignant human lymphoid cells.

Authors:  L M Neckers; W K Funkhouser; J B Trepel; J Cossman; H G Gratzner
Journal:  Exp Cell Res       Date:  1985-02       Impact factor: 3.905

View more
  3 in total

1.  Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Authors:  Michael G Alexandrakis; Freda H Passam; Despina S Kyriakou; Constantina Dambaki; George Katrinakis; George Tsirakis; John Konsolas; Efstathios N Stathopoulos
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

2.  FragViz: visualization of fragmented networks.

Authors:  Miha Stajdohar; Minca Mramor; Blaž Zupan; Janez Demšar
Journal:  BMC Bioinformatics       Date:  2010-09-22       Impact factor: 3.169

3.  Gene and protein analysis reveals that p53 pathway is functionally inactivated in cytogenetically normal Acute Myeloid Leukemia and Acute Promyelocytic Leukemia.

Authors:  Julia Abramowitz; Tzahi Neuman; Riki Perlman; Dina Ben-Yehuda
Journal:  BMC Med Genomics       Date:  2017-03-24       Impact factor: 3.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.